ABUS vs TXN · P/E 5.4, rev $6.2M vs P/E 52, rev $17.68B
Arbutus Biopharma Corp (ABUS) versus Texas Instruments Incorporated (TXN) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Texas Instruments Incorporated (TXN) is a semiconductors company listed on NASDAQ.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported TXN revenue for 2025-12-31 was $17.68B. Net income was $5.00B. Revenue was up 13.0% from 2024-12-31 to 2025-12-31. TXN currently screens at market cap $274.74B and trailing P/E 51.7.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. TXN currently screens at market cap $274.74B and trailing P/E 51.7.
Not investment advice. Open the ABUS and TXN stock pages for the full models.
Not investment advice.